RELATED: J&J's Stelara, squeezed in psoriasis, grabs new market with Crohn's approvalįor J&J, though, whatever sales Tremfya can generate will supplement those from older blockbusters threatened by new competition, including the next-gen psoriasis entrants. All three of those rivals target interleukin-17, and as Credit Suisse analyst Vamil Divan wrote in a May note to clients, J&J is pitting Tremfya against Cosentyx in a head-to-head trial it hopes will prove the new med superior.Įven so, some industry watchers wonder “ how the product might differentiate itself from competitors,” especially in such an “increasingly crowded” field, Divan said in the same note, adding that experts have previously told him “they did not feel there was a need for many newer agents.” Tremfya works differently from its peers: It selectively blocks interleukin-23, a cytokine involved in inflammatory and immune responses. Analysts expect the J&J med to grab enough share to yield $1.56 billion in 2022 sales, according to EvaluatePharma's latest World Preview report. And now, Tremfya will join Cosentyx, Eli Lilly’s Taltz and Valeant’s Siliq in a market that’s recently exploded with new-age options. The green light came quickly for J&J, which cashed in a priority review voucher to get to market as quickly as possible. RELATED: The top 10 drug launches of 2017 The New Jersey pharma said in a statement that it will “work closely with payers, providers and pharmacy benefit managers to ensure Tremfya is broadly accessible and affordable for patients,” adding that it offers a copay card for eligible patients that’ll sink out-of-pocket costs to $5 or less per dose.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |